Personalis (PSNL) to Announce Quarterly Earnings on Tuesday

Personalis (NASDAQ:PSNL) is expected to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.25) per share and revenue of $16.6880 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 5:00 PM ET.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Stock Up 1.7%

PSNL stock opened at $11.98 on Tuesday. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -11.75 and a beta of 2.24. The firm has a 50 day moving average of $11.69 and a two-hundred day moving average of $9.09. Personalis has a 12 month low of $3.84 and a 12 month high of $16.39.

Wall Street Analysts Forecast Growth

PSNL has been the topic of several recent research reports. Zacks Research lowered Personalis from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. TD Cowen reissued a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Lake Street Capital lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, July 20th. Finally, Needham & Company LLC cut Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Personalis currently has an average rating of “Hold” and a consensus target price of $14.25.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 100,000 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares of the company’s stock, valued at $3,103,215.90. The trade was a 29.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,620,618.94. This trade represents a 20.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock worth $5,599,929 in the last quarter. Insiders own 4.20% of the company’s stock.

Institutional Trading of Personalis

Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Personalis in the 2nd quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd increased its position in Personalis by 184.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after buying an additional 3,592 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Personalis in the fourth quarter valued at approximately $82,000. Finally, DRW Securities LLC bought a new stake in shares of Personalis in the fourth quarter valued at approximately $83,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.